Sign inJoin waitlistJoin the waitlist

Luis Fayad

Physician · University of Texas M D Anderson Cancer Center

Credentials: · ·

History

University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
1994–1997
University of Texas Health Science Center at Houston
1993–1994
Internal Medicine
University of Miami/Jackson Health System
1990–1993
Doctor of Medicine
1981–1985

Research

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
Nature Medicine · 2020 · 536 citations
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma
Journal of Clinical Oncology · 2005 · 439 citations
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose…
Journal of Clinical Oncology · 2005 · 438 citations

Sattva Neelapu
106 papers
Fredrick Hagemeister
98 papers
Jason Westin
93 papers · 1 as a fellow
JR
Jorge Romaguera
88 papers
Loretta Nastoupil
85 papers · 13 as a fellow
FS
Felipe Samaniego
81 papers
NF
Nathan Fowler
79 papers
Maria Rodriguez
75 papers
YO
Yasuhiro Oki
63 papers · 2 as a fellow
MF
Michelle Fanale
61 papers
AY
Anas Younes
53 papers
LW
Luhua Wang
53 papers

Grants

FLT-PET/CT for Therapy Monitoring of DLBCL
National Cancer Institute · R01
PI · $2M · University of California Los Angeles
2011–2018

Clinical trials

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2005–2017
Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2002–2005
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Study chair · Unknown · Phase 1
Theradex
2002